Evidence map›Paper›PMID 42293249›Full record

ArticleMolecular therapy. Nucleic acids2026

Cell type-stratified immunogenetic framework reveals immune drivers and therapeutic targets in kidney stone disease.

Dianjie Zeng, Lingfei Zhu, Jiachen Liu, Xiaorui Qiu, Leyi Chen, Chenming Wei, Yinhuai Wang, Zebin Deng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dianjie ZengDepartment of Urology, The Second Xiangya Hospital at Central South University, Changsha, Hunan 410011, China.
Lingfei ZhuDepartment of Urology, The Second Xiangya Hospital at Central South University, Changsha, Hunan 410011, China.
Jiachen LiuDepartment of Urology, The Second Xiangya Hospital at Central South University, Changsha, Hunan 410011, China.
Xiaorui QiuDepartment of Orthopedic, Xiangya Hospital at Central South University, Changsha, Hunan, China.
Leyi ChenSchool of Medicine, Washington University, St. Louis, MO, USA.
Chenming WeiSchool of Medicine, Washington University, St. Louis, MO, USA.
Yinhuai WangDepartment of Urology, The Second Xiangya Hospital at Central South University, Changsha, Hunan 410011, China.
Zebin DengDepartment of Urology, The Second Xiangya Hospital at Central South University, Changsha, Hunan 410011, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite growing recognition of immune involvement in kidney stone disease (KSD), its immunogenetic basis remains unclear. We applied a cell type-stratified immunogenetic framework, integrating single-cell

Indexed as

colocalizationgenetic regulatory architectureimmune cell–specific regulationkidney stone diseaseMT: Clinical Applicationssingle-cell eQTLtarget prioritization

Identifiers

PMID42293249
PMCPMC13264055

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.